The NVAX Data Debacle

On Tuesday, August 4th, 2020, Novavax (NVAX) published results from its Phase 1/2 study of its COVID vaccine. A journalistic error caused the shares to experience a $75 swing in after hours trading. The episode serves as a good reminder for Investor Relations Officers to make sure they get the messaging right and remain in control of their narrative.